Clinical trial
Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive…
NCT00040443 · RespireRx, Industry · Completed
Key facts
| NCT number | NCT00040443 |
|---|---|
| Title | Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment. |
| Official title | Efficacy And Safety Of CX516 (900 mg t.i.d.) In Elderly Participants With Mild Cognitive Impairment. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 4-week Study. |
| Lead sponsor | RespireRx, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mild Cognitive Impairment |
| Intervention type | Drug |
| Interventions | CX516, Placebo |
| Enrollment | 175 |
| Start date | Apr 1, 2002 |
| Primary completion | Aug 1, 2003 |
| Completion | Jun 1, 2004 |
| First posted | Jun 28, 2002 |
| Last update posted | Jul 23, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: